INmune Bio, Inc.
INmune Bio, Inc.（INMB）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
inmb · 股价预测 · 9 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 9 位华尔街分析师
Buy
9 位分析师
共识
评级分布
12 个月目标价
High
$22.00
Consensus
$22.00
+1674.2% upside
Low
$22.00
Median: $22 · Last Close: $1.24
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.19 | ↓ 3.75% |
1-day model range: $1.17–$1.22. Peak: $1.22 (-3.75%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · INMB · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-11 | LUCID CAPITAL MARKETS | Upgrade ↑ | Neutral→Buy |
| 2025-07-02 | Maxim Group | Maintains | Buy→Buy |
| 2025-07-01 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-07-01 | Scotiabank | Downgrade ↓ | Sector Outperform→Sector Underperform |
| 2025-02-13 | Maxim Group | Maintains | Buy→Buy |
| 2025-02-11 | Scotiabank | Maintains | Sector Outperform→Sector Outperform |
| 2023-06-01 | Baird | Maintains | Outperform→Outperform |
| 2022-05-24 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2022-05-24 | BTIG | Maintains | Buy→Buy |
| 2022-01-24 | B. Riley Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on INmune Bio, Inc. (INMB) stock. Of the recent 22 rating actions, 1 were upgrades and 3 were downgrades. 9 analysts currently cover INMB.
分析师推荐趋势
INMB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$0M
↓ 99.5% YoY
Revenue Next Year
$6M
↑ 4670.0% YoY
EPS This Year
$-0.70
EPS Next Year
$-0.76
↑ 7.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast INMB EPS of $-0.70 for the current fiscal year, based on estimates from 2 analysts. The INMB revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
INMB 股价预测由两类独立数据源支撑：来自 9 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。INMB 的共识目标价为 $22.00（+1674.2% 上行空间），分析师共识为 Buy。
INMB 的短期预测（明日）为 $1.19（-3.75%）。
INmune Bio, Inc. 在 NASDAQ 上市，代码 INMB。INMB 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。
常见问题
INMB 预测 · 8 个问题根据 9 位华尔街分析师，INMB 的 12 个月平均目标价为 $22.00，最高 $22.00、最低 $22.00。若有图表，中位目标价可在上方查看。相对当前价 $1.24，隐含约 +1674.2% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.